Skip to main content
Top
Published in: Acta Neurochirurgica 11/2010

01-11-2010 | Clinical Article

MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status

Authors: Jonathan H. Sherman, Daniel M. Prevedello, Lubdha Shah, Prashant Raghavan, Nader Pouratian, Robert M. Starke, M. Beatriz S. Lopes, Mark E. Shaffrey, David Schiff

Published in: Acta Neurochirurgica | Issue 11/2010

Login to get access

Abstract

Purpose

Patients with oligodendrogliomas with allelic loss of chromosomal arm 1p and 19q have been shown, especially with anaplastic oligodendrogliomas, to have both a better initial and long-term response to chemotherapy as well as an improved overall survival. Effective treatment of patients with brain tumors requires accurate diagnostic techniques. MR imaging can be used to help differentiate between low- and high-grade tumors. We hypothesize that certain MR imaging characteristics can be used to differentiate between patients with and without 1p and 19q deletion.

Methods

Using the clinical database at the University of Virginia Neuro-Oncology Center, we identified adult patients with grade II and III oligodendroglial tumors who underwent treatment from 2002 to 2007. Age at diagnosis, gender, tumor grade, chromosomal deletion status, duration of follow-up, and MR imaging characteristics were analyzed; the latter was read by a blinded neuroradiologist.

Results

One hundred and four patients met the inclusion criteria. Of these patients, 44 manifested 1p/19q co-deletion and 60 patients lacked this deletion. The greatest cross-sectional area (mean) of the tumor measured 23.4 cm2 for patients with the co-deletion and 31.7 cm2 for patients with intact alleles (p = 0.008). In addition, inner table thinning was noted directly adjacent to seven tumors with intact 1p and 19q alleles and in no tumors with the 1p/19q co-deletion (p = 0.020). Amongst patients with pure oligodendrogliomas, those with 1p/19q co-deletion had tumors more often confined to a single lobe as compared with those patients without the co-deletion (p = 0.023). Finally, tumors with intact alleles were more often found in the temporal lobe (45.0%) as compared with co-deleted tumors (22.7%) (p = 0.011).

Conclusion

MR imaging is a valuable imaging modality for differentiating between oligodendrogliomas with or without the 1p/19q deletion. While imaging will never replace definitive tissue diagnosis, imaging characteristics such as tumor size, location, and overlying skull thinning can assist clinicians in assessing patients with oligodendroglial tumors prior to surgical or medical intervention.
Literature
1.
go back to reference Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37:399–403PubMed Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37:399–403PubMed
2.
go back to reference Barker FG 2nd, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941CrossRefPubMed Barker FG 2nd, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941CrossRefPubMed
3.
go back to reference Bigner SH, Rasheed BK, Wiltshire R, McLendon RE (1999) Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncology 1:52–60PubMed Bigner SH, Rasheed BK, Wiltshire R, McLendon RE (1999) Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncology 1:52–60PubMed
4.
go back to reference Brown R, Zlatescu MC, Sijben A, Roldan G, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357–2362CrossRefPubMed Brown R, Zlatescu MC, Sijben A, Roldan G, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357–2362CrossRefPubMed
5.
go back to reference Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefPubMed Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefPubMed
6.
go back to reference Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021PubMed Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021PubMed
7.
go back to reference Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed
8.
go back to reference Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G (2009) Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 53:305–309CrossRefPubMed Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G (2009) Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 53:305–309CrossRefPubMed
9.
go back to reference Caseiras GB, Chheang S, Babb J, Rees JH, Pecerrelli N, Tozer DJ, Benton C, Zagzag D, Johnson G, Waldman AD, Jager HR, Law M (2010) Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 73:215–220CrossRefPubMed Caseiras GB, Chheang S, Babb J, Rees JH, Pecerrelli N, Tozer DJ, Benton C, Zagzag D, Johnson G, Waldman AD, Jager HR, Law M (2010) Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 73:215–220CrossRefPubMed
10.
go back to reference Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber ML, Lu S, Zagzag D (2000) Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21:881–890PubMed Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber ML, Lu S, Zagzag D (2000) Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21:881–890PubMed
11.
go back to reference Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed
12.
go back to reference Cooper ERA (1935) The relation of oligodendrocytes and astrocytes in cerebral tumors. J Pathol Bacteriol 41:259–266CrossRef Cooper ERA (1935) The relation of oligodendrocytes and astrocytes in cerebral tumors. J Pathol Bacteriol 41:259–266CrossRef
13.
go back to reference Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, Houtteville JP, Chajari MH, Bouvard G (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27:778–787CrossRefPubMed Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, Houtteville JP, Chajari MH, Bouvard G (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27:778–787CrossRefPubMed
14.
go back to reference Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119:84–90CrossRefPubMed Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119:84–90CrossRefPubMed
15.
go back to reference Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMed Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMed
16.
go back to reference Higa T, Maetani S, Yoichiro K, Nabeshima S (2001) TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med 26:119–124CrossRefPubMed Higa T, Maetani S, Yoichiro K, Nabeshima S (2001) TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med 26:119–124CrossRefPubMed
17.
go back to reference Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefPubMed Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefPubMed
18.
go back to reference Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed
19.
go back to reference Jenkinson MD, Smith TS, Brodbelt AR, Joyce KA, Warnke PC, Walker C (2007) Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 26:1405–1412CrossRefPubMed Jenkinson MD, Smith TS, Brodbelt AR, Joyce KA, Warnke PC, Walker C (2007) Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 26:1405–1412CrossRefPubMed
20.
go back to reference Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G, van den Bent MJ (2007) Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545–551CrossRefPubMed Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G, van den Bent MJ (2007) Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545–551CrossRefPubMed
21.
go back to reference Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 238:658–667CrossRefPubMed Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 238:658–667CrossRefPubMed
22.
go back to reference Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ (2006) Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58:1099–1107, discussion 1099–1107CrossRefPubMed Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ (2006) Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58:1099–1107, discussion 1099–1107CrossRefPubMed
23.
go back to reference Levivier M, Wikler D Jr, Massager N, David P, Devriendt D, Lorenzoni J, Pirotte B, Desmedt F, Simon S Jr, Goldman S, Van Houtte P, Brotchi J (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97:542–550CrossRefPubMed Levivier M, Wikler D Jr, Massager N, David P, Devriendt D, Lorenzoni J, Pirotte B, Desmedt F, Simon S Jr, Goldman S, Van Houtte P, Brotchi J (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97:542–550CrossRefPubMed
24.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMed Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMed
25.
go back to reference Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098–1104CrossRefPubMed Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098–1104CrossRefPubMed
26.
go back to reference Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737CrossRefPubMed Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frenay M, Tijssen CC, Lacombe D, van den Bent MJ (2007) Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 25:5731–5737CrossRefPubMed
27.
go back to reference McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 30:34–44CrossRefPubMed McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 30:34–44CrossRefPubMed
28.
go back to reference Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306CrossRefPubMed Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306CrossRefPubMed
29.
go back to reference Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237CrossRefPubMed Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237CrossRefPubMed
30.
go back to reference Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D (2007) Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 3:628–639CrossRefPubMed Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D (2007) Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 3:628–639CrossRefPubMed
31.
go back to reference Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281–288CrossRefPubMed Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281–288CrossRefPubMed
32.
go back to reference Stokkel M, Stevens H, Taphoorn M, Van Rijk P (1999) Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera–a pilot study. Nucl Med Commun 20:411–417CrossRefPubMed Stokkel M, Stevens H, Taphoorn M, Van Rijk P (1999) Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera–a pilot study. Nucl Med Commun 20:411–417CrossRefPubMed
33.
go back to reference van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145PubMed van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145PubMed
34.
go back to reference Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen CJ, Vandertop WP, Slotman BJ, Postma TJ (2003) Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21:3559–3565CrossRefPubMed Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen CJ, Vandertop WP, Slotman BJ, Postma TJ (2003) Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21:3559–3565CrossRefPubMed
35.
go back to reference Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, Joyce KA, Broome J, Kopitski K, Prosser J, Smith T, Vinjamuri S, Warnke PC (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191CrossRefPubMed Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, Joyce KA, Broome J, Kopitski K, Prosser J, Smith T, Vinjamuri S, Warnke PC (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191CrossRefPubMed
36.
go back to reference Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715PubMed Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715PubMed
Metadata
Title
MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status
Authors
Jonathan H. Sherman
Daniel M. Prevedello
Lubdha Shah
Prashant Raghavan
Nader Pouratian
Robert M. Starke
M. Beatriz S. Lopes
Mark E. Shaffrey
David Schiff
Publication date
01-11-2010
Publisher
Springer Vienna
Published in
Acta Neurochirurgica / Issue 11/2010
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-010-0743-1

Other articles of this Issue 11/2010

Acta Neurochirurgica 11/2010 Go to the issue